drugset / Trial / NCT04577807
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibitor.
Timeline
- Start
- 2020-11-17
- Primary completion
- 2024-11-15
- Completion
- 2024-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lerapolturev | Other / unclassified | 1.6e+09 unknown | Other |